Saluda Medical, Inc., a leader in the advancement of neuromodulation technologies aimed at improving the lives of patients with chronic neurological disorders, has formally declared EVA’s full-scale commercial availability, its most recent advancements in sensing technology, all around the United States. This comes after EVA was approved by the US Food and Drug Administration in December 2024. All patients now using the Evoke® SmartLoopTM System can easily integrate with EVA technology, guaranteeing compatibility and instant use for current users.
EVA represents a significant evolution in spinal cord stimulation therapy by introducing a level of precision previously unattainable. The technology works as an enhancement to the established Evoke System, continuously scanning and interpreting the patient’s spinal cord activity to deliver personalized stimulation. Through real-time analysis of the patient’s neural response, measured by the evoked compound action potential (ECAP), EVA adjusts stimulation dynamically, maintaining therapy at the prescribed level without manual intervention. This personalized and adaptive approach aims to optimize outcomes and deliver more consistent relief for patients dealing with chronic pain.
Mike Mathias, Chief Commercial Officer at Saluda Medical, emphasized that the full launch of EVA marks a major milestone in spinal cord stimulation therapy. According to Mathias, the introduction of objective, automated dosing not only enhances clinical outcomes but also simplifies the therapy experience for patients by automating many of the manual programming steps previously required. Following its FDA approval, EVA has already been deployed in over 3,000 commercial patient sessions during a limited initial rollout, demonstrating both demand and practical effectiveness.
Saluda Medical plans to showcase new clinical findings related to EVA at the upcoming American Society of Pain and Neuroscience (ASPN) Annual Conference, scheduled for July 2025 in Miami, Florida. The company will present 11 abstracts and a key oral presentation, expanding on its substantial body of clinical research, which now includes more than 37 published studies. These findings will further validate the system’s benefits, complementing results from the pivotal EVOKE Study that highlighted sustained efficacy over a three-year period.
Dr. Jason Pope, Founder and CEO of Evolve Restorative Center, praised the Evoke SmartLoop System equipped with EVA for its ability to provide objective dosing that leads to more stable and long-lasting results in spinal cord stimulation therapy. He noted that upcoming data will underscore how the technology not only enhances diagnostic accuracy during trial phases but also ensures ongoing therapeutic effectiveness without diminishing over time. Saluda Medical’s EVA technology is thus positioned as a groundbreaking step forward in the treatment of chronic neurological pain, offering both precision and durability in therapeutic outcomes.
